IDEXX Laboratories, Inc. (IDXX) jumps 19% on earnings
IDEXX Laboratories, Inc. (IDXX) jumps after a strong Q3 report and higher full-year guidance. The veterinary diagnostics leader beat earnings estimates, posted double-digit revenue growth, and raised its 2026 outlook, fueling a sharp revaluation as investors responded to improving fundamentals.
IDEXX Laboratories, Inc. (IDXX) jumped 19.15% after reporting a strong Q3 2026 earnings beat and raising full-year guidance. The rally was driven by $1.214 billion in revenue, $4.01 in diluted EPS, and double-digit growth across core veterinary diagnostics businesses, signaling that demand and pricing remain healthy. For investors, the move confirms improving fundamentals, but the stock’s premium valuation means execution now matters more than ever.
IDEXX Laboratories (IDXX) jumps 19.15% to $656.7497 at the noon ET print on November 2, 2026. Relative volume reached 1.8 times the 200-day average, signaling that investors are aggressively repricing the veterinary diagnostics leader after a strong quarterly report and a higher full-year outlook.
Key Takeaways
IDXX jumps 19.15% after reporting Q3 2026 revenue of $1.214 billion and diluted EPS of $4.01.
The clearest catalyst is a beat-and-raise quarter, including higher full-year revenue and EPS guidance.
Revenue grew 10% year over year, while EPS rose 18% on a reported basis and 22% on a comparable basis.
The business remains highly competitive and financially strong, but a P/E of 38.7358 leaves less room for execution mistakes.
Why IDEXX Laboratories Stock Is Jumping Today
The catalyst arrived before the market opened on November 2, when IDEXX reported Q3 2026 results and raised its full-year guidance. The timing matches the price action: IDXX gained sharply in premarket trading before extending the move during regular hours. That pattern points to earnings, rather than a random burst of trading interest, as the main reason for the advance.
IDEXX reported diluted EPS of $4.01 against a $3.71 estimate in the earnings history. Revenue reached $1.214 billion, up 10% from the prior year on both a reported and organic basis. The company also raised full-year 2026 EPS guidance to $14.96-$15.16 and revenue guidance to $4.741 billion-$4.767 billion.
The guidance increase adds weight to the reaction. IDEXX lifted the revenue midpoint by about $32 million and the EPS midpoint by $0.25 versus its prior outlook. It also absorbed acquisition impacts while raising expectations, which gives the market a stronger operating signal than a quarterly beat alone.
IDEXX Q3 Earnings Show Broad Veterinary Diagnostics Growth
The quarter showed breadth across IDEXX’s core operations. Companion Animal Group revenue grew 10% on both reported and organic measures. Reference laboratory diagnostics and consulting services also grew 10% on both measures.
That mix matters because reference laboratory growth came from testing volume, new customer gains, and price realization. Those three drivers point to more than a one-time pricing benefit. They also support the view that IDEXX continues to expand usage within veterinary practices.
The company’s model combines point-of-care analyzers, recurring consumables, reference laboratory services, and software tools. After a clinic adopts an analyzer, recurring tests and workflow products can deepen the customer relationship. This installed-base model helps explain why investors often assign IDEXX a premium valuation when growth remains steady.
IDXX Valuation and Competitive Position After the Earnings Surge
IDEXX has a market capitalization of $51.74 billion, EPS of $14.23, and a P/E of 38.7358. That multiple reflects a premium business, not a bargain stock. The Q3 growth rate and higher guidance help support the valuation, but the price still requires continued earnings delivery.
Competition remains serious. IDEXX identifies Mars and Antech Diagnostics, Heska, and Zoetis with Abaxis among its competitors. Still, IDEXX operates at meaningful scale, serving customers in more than 175 countries and territories with approximately 11,000 employees.
The latest results reinforce its competitive position. Reference lab growth from testing volume, customer additions, and price realization shows that IDEXX can monetize its installed base while adding accounts. That combination supports a durable moat, although the P/E of 38.7358 leaves the stock sensitive to any slowdown in revenue or EPS growth.
What the IDXX Outlook Means for Investors After a 19.15% Gain
The forward outlook improved in a measurable way. Full-year revenue guidance now stands at $4.741 billion-$4.767 billion, while EPS guidance stands at $14.96-$15.16. The company therefore enters the remainder of 2026 with a higher earnings framework than it had before the Q3 report.
Analyst sentiment adds useful valuation context, but it did not create today’s move. Goldman Sachs initiated IDXX with a Buy rating and a $740 target on October 16. UBS lowered its target to $627 from $670 on October 27. The current analyst consensus target is $692.33, with a range of $627 to $740.
For investors, the practical distinction is simple: the business signal improved, while the entry price became more demanding. A 19.15% one-day gain and 1.8x relative volume show strong conviction, but they also raise the risk of chasing a sharp repricing. A staggered position or a valuation-based entry plan offers more discipline than treating the earnings gap as a guaranteed continuation.
IDEXX’s Q3 report gives the rally a concrete foundation: $1.214 billion in revenue, $4.01 in EPS, double-digit organic growth, and higher 2026 guidance. The company’s recurring diagnostics model and competitive scale remain attractive, yet the 38.7358 P/E demands continued execution. The earnings catalyst is strong, but investors still need to separate business quality from the price paid for it.
IDXX is up because IDEXX reported a strong Q3 2026 beat and raised its full-year revenue and EPS guidance. Investors are reacting to the combination of faster growth, better profitability, and a stronger outlook.
+Should I buy IDXX stock now?
The earnings report supports the business case for IDXX, but the stock already jumped sharply and trades at a premium valuation. A more disciplined approach is to wait for a better entry or size positions gradually.
+Did IDEXX beat earnings estimates this quarter?
Yes. IDEXX reported diluted EPS of $4.01, above the $3.71 estimate, and revenue came in at $1.214 billion. The company also raised its full-year 2026 outlook.
+What does the higher guidance mean for IDXX investors?
Higher guidance suggests IDEXX expects stronger sales and earnings for the rest of 2026. That supports the rally, but it also means future upside depends on the company continuing to deliver on those raised expectations.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on IDXX?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.